U.S. FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen
This article was originally published in PharmAsia News
FDA has deemed FibroGen's response to a clinical hold on two oral anemia therapy candidates complete, allowing Phase II trials of the compounds to resume, FibroGen's development partner, Astellas Pharma, announced April 2
You may also be interested in...
AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
Astellas Taps Pfizer Exec To Run New Global Development HQ
Long-time Pfizer exec Steven Ryder will become president of Astellas Pharma's new headquarters for global development in Deerfield, Ill., effective April 1, the Tokyo-based company announced March 4
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).